Get the Stockscreener App
17.50
1.10%
0.19
After Hours:
17.69
0.19
+1.09%
Sarepta Therapeutics Inc stock is traded at $17.50, with a volume of 2.87M.
It is up +1.10% in the last 24 hours and down -22.22% over the past month.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
See More
Previous Close:
$17.31
Open:
$17.28
24h Volume:
2.87M
Relative Volume:
0.94
Market Cap:
$1.85B
Revenue:
$2.18B
Net Income/Loss:
$-64.32M
P/E Ratio:
-18.15
EPS:
-0.9641
Net Cash Flow:
$91.18M
1W Performance:
-3.95%
1M Performance:
-22.22%
6M Performance:
-24.18%
1Y Performance:
-24.31%
1-Day Range:
$16.98
$17.66
1-Week Range:
$16.98
$18.25
52-Week Range:
$14.68
$25.32
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Name
Sarepta Therapeutics Inc
Sector
Industry
Phone
617-274-4000
Address
215 FIRST STREET, CAMBRIDGE, MA
Compare SRPT vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.50 | 1.97B | 2.18B | -64.32M | 91.18M | -0.9641 |
VRTX
Vertex Pharmaceuticals Inc
|
505.64 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
196.48 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
742.12 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
928.44 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
200.87 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Dec-09-25 | Initiated | Wedbush | Outperform |
| Nov-05-25 | Upgrade | Mizuho | Neutral → Outperform |
| Sep-22-25 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jul-29-25 | Upgrade | Barclays | Underweight → Equal Weight |
| Jul-29-25 | Initiated | Bernstein | Mkt Perform |
| Jul-29-25 | Reiterated | H.C. Wainwright | Sell |
| Jul-29-25 | Upgrade | JP Morgan | Underweight → Neutral |
| Jul-29-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-28-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Jul-25-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-24-25 | Initiated | Citigroup | Sell |
| Jul-23-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-22-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jul-21-25 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-21-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-21-25 | Downgrade | Mizuho | Outperform → Neutral |
| Jul-21-25 | Downgrade | Needham | Hold → Underperform |
| Jul-21-25 | Downgrade | UBS | Buy → Neutral |
| Jul-18-25 | Downgrade | Needham | Buy → Hold |
| Jun-20-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Jun-18-25 | Downgrade | TD Cowen | Buy → Hold |
| Jun-17-25 | Initiated | Wolfe Research | Peer Perform |
| Jun-16-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jun-16-25 | Downgrade | BofA Securities | Buy → Neutral |
| Jun-16-25 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jun-16-25 | Downgrade | H.C. Wainwright | Neutral → Sell |
| Jun-16-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-16-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jun-06-25 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| May-08-25 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-11-25 | Initiated | Wells Fargo | Overweight |
| Apr-02-25 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Mar-31-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Hold |
| Nov-27-24 | Reiterated | Needham | Buy |
| Nov-25-24 | Initiated | H.C. Wainwright | Sell |
| Nov-07-24 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Jul-29-24 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Jun-26-24 | Downgrade | Citigroup | Buy → Neutral |
| May-31-24 | Initiated | Piper Sandler | Overweight |
| May-28-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| May-14-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-31-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-13-23 | Resumed | Citigroup | Buy |
| Dec-12-23 | Initiated | Deutsche Bank | Buy |
| Nov-21-23 | Initiated | Wedbush | Outperform |
| Oct-31-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-31-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-23-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-04-23 | Initiated | Citigroup | Buy |
| Mar-01-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-22-22 | Reiterated | BTIG Research | Buy |
| Dec-16-22 | Upgrade | UBS | Neutral → Buy |
| Apr-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-05-22 | Reiterated | Needham | Buy |
| Dec-09-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-15-21 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Jan-12-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-11-21 | Downgrade | UBS | Buy → Neutral |
| Jan-08-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Jan-08-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-08-21 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Oct-28-20 | Initiated | UBS | Buy |
| Aug-25-20 | Initiated | Raymond James | Outperform |
| Aug-20-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-31-20 | Initiated | Mizuho | Buy |
| Nov-01-19 | Initiated | Guggenheim | Buy |
| Aug-21-19 | Reiterated | Needham | Buy |
| Jul-09-19 | Reiterated | Morgan Stanley | Overweight |
| Jul-01-19 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-11-19 | Reiterated | Credit Suisse | Outperform |
| Oct-12-18 | Initiated | Bernstein | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Sep-26-18 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-14-18 | Resumed | BofA/Merrill | Buy |
| Sep-06-18 | Initiated | Credit Suisse | Outperform |
| Aug-01-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-21-18 | Reiterated | Robert W. Baird | Outperform |
| Jun-20-18 | Reiterated | Needham | Buy |
| Jun-19-18 | Reiterated | H.C. Wainwright | Buy |
View All
Sarepta Therapeutics Inc Stock (SRPT) Latest News
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 30, 2026 - biospace.com
Sarepta Therapeutics Is Maintained at Neutral by JP Morgan - Moomoo
Sarepta Therapeutics stock falls 1.28 percent as DMD data land - AD HOC NEWS
Sarepta Reports ELEVIDYS Duchenne Trial Data - grafa.com
Sarepta Therapeutics (SRPT) Reports Positive Functional Data for Older Duchenne Muscular Dystrophy Patients - GuruFocus
Sarepta presents Elevidys data in older Duchenne patients - Investing.com
Sarepta Therapeutics Presents New Data at 2026 World Muscle Society Annual Congress Demonstrating Safety and Clinically Meaningful Functional Benefit of ELEVIDYS (delandistrogene moxeparvovec) in Older Ambulatory Patients with Duchenne - Sarepta Therapeutics
Operating cash flow per share of Sarepta Therapeutics, Inc. – HAN:AB3A - TradingView
Capricor Or Sarepta: Two DMD Stocks Enter A High-Stakes Week – Which One Has More Upside? - Stocktwits
Liquidity Mapping Around (SRPT) Price Events - Stock Traders Daily
SRPT Reiterates by Needham -- Maintains Underperform Rating - GuruFocus
Sarepta Therapeutics, Inc. Revenue Breakdown – LS:A1J1BH - TradingView
Why Sarepta Therapeutics (SRPT) Is Down 7.2% After AAVrh74 Patent Peace With REGENXBIO And UPenn - Yahoo Finance
SRPT Should I Buy - Intellectia AI
Sarepta Therapeutics Announces Presentations at 2026 World Muscle Society Annual Congress - BioSpace
Regenxbio stock gains on positive gene therapy trial data By Investing.com - Investing.com UK
Sarepta Settles Regenxbio’s Patent Infringement Claims in $39M Deal - GenomeWeb
Jefferies reiterates Sarepta Therapeutics stock rating on pipeline potential By Investing.com - Investing.com Canada
Sarepta to pay Regenxbio $39M to settle gene therapy claims; Vida eyes fourth fund - Endpoints News
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27th Annual Neuromuscular Study Group Scientific Meeting - BioSpace
Sarepta to present gene therapy data at neuromuscular meeting - Investing.com
Sarepta to present gene therapy data at neuromuscular meeting By Investing.com - Investing.com Canada
Sarepta Therapeutics to Present New Data from its Neuromuscular Portfolio at 27 - Business Wire
Sarepta Therapeutics, Inc. (SRPT.MX) Stock Forum & Discussion - Yahoo! Finance Canada
Morgan Stanley Views Sarepta CEO Transition As A ‘Positive’ – So, Why Is It Cautious On SRPT Stock In The Near Term? - stocktwits.com
This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next - Stocktwits
REGENXBIO and Sarepta Resolve ELEVIDYS Patent Litigation with $39 Million Settlement - Kalkine Media
Sarepta Therapeutics, Inc. (SRPT) Stock Forecasts - Yahoo Finance
Sarepta Resolves AAVrh74 Gene Therapy Patent Dispute - TipRanks
Sarepta Therapeutics Drops 7.1% Amid Sector-Wide Selling - AlphaStreet
SRPT Looks 81.5% Undervalued on GF Value™ Amid Rare Disease Tria - GuruFocus
Sarepta Therapeutics stock gains analyst support after mixed rating signals - AD HOC NEWS
Sarepta Therapeutics stock holds near USD 19.76 after analyst reset - AD HOC NEWS
Sarepta Therapeutics, Inc. (SRPT) Stock forecasts - Yahoo Finance UK
Price-Driven Insight from (SRPT) for Rule-Based Strategy - Stock Traders Daily
Demand Stabilization Might Change The Case For Investing In Sarepta Stock (SRPT) - simplywall.st
Massachusetts Judge Bars Sarepta Therapeutics Investor Suit Over Alleged Risk Misstatements - Lawxy AI
Sarepta Bats Away Investors’ Duchenne Therapy Safety Lawsuit (1) - Bloomberg Law News
Sarepta Therapeutics, Inc.Common Stock (NQ: SRPT - The Chronicle-Journal
Sarepta Sees ELEVIDYS Demand Stabilizing as FSHD, DM1 Readouts Near - Yahoo Finance
Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 08:30 AM - marketscreener.com
Sarepta Hits Fresh Hurdle As Court Revives Patent Lawsuit With Regenxbio Over Muscular Disorder Therapy - Stocktwits
Sarepta Therapeutics Drops 5.5% Amid Sector-Wide Selling - AlphaStreet
SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling - Stocktwits
SRPT Looks 79.1% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Sarepta Therapeutics climbs 10%, rebounding from recent slide (SRPT:NASDAQ) - Seeking Alpha
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving High - Benzinga
H.C. Wainwright reiterates Sarepta stock Sell rating at $5 target By Investing.com - Investing.com Canada
Sarepta (NASDAQ: SRPT) CFO now holds 121,792 shares after tax withholding - Stock Titan
Tax on stock award trims Sarepta (NASDAQ: SRPT) EVP stake to 115,519 shares - Stock Titan
Sarepta (SRPT) COO reports tax share withholding after RSU vesting - Stock Titan
Sarepta Therapeutics Inc Stock (SRPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):